Event-free survival (EFS) analysis of neoadjuvant taxane/ carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

L Gianni, C Huang, D Egle, B Bermejo, C Zamagni, M Thill, AA Torres, G Bianchini, ES Fernandez, S Russo, EM Ciruelos, R Greil, V Semiglazov, MA Colleoni, CM Kelly, G Mariani, L Del Mastro, R Spezia, H Ali, G Viale

Research output: Contribution to journalpublished Abstract (Journal)peer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1258-S1259
JournalANNALS OF ONCOLOGY
Volume34
DOIs
Publication statusPublished - 2023

Cite this